We’re improving your experience!

×

Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.

Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.

Stay tuned for these updates, and thank you for being part of our community!

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02584647
Title Combination of PLX3397 and Sirolimus in Unresectable Sarcoma (Phase 1) and Malignant Peripheral Nerve Sheath Tumors (Phase 2)
Acronym PLX3397
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Gary Schwartz
Indications
Therapies
Age Groups: adult
Covered Countries USA


No variant requirements are available.